Table 1 Demographic and clinical characteristics.
Characteristic | Participants, no. (%) | ||
|---|---|---|---|
Tocilizumab cohort (N = 25) | Control cohort (N = 62) | P value | |
Age, mean (SD), y | 60.2 (10.6) | 53.9 (10.1) | 0.01 |
Female sex | 10 (40) | 21 (34) | 0.59 |
Race | 0.14 | ||
Caucasian/White | 23 (92) | 61 (98) | |
Asian American | 1 (4) | 0 (0) | |
Latino/a | 1 (4) | 0 (0) | |
Native American | 0 (0) | 1 (2) | |
Body mass index, mean (SD) | 28.4 (4.6) | 28.8 (4.9) | 0.74 |
Educationa,b | 0.90 | ||
<12 years | 1 (4) | 3 (5) | |
High school | 8 (33) | 20 (33) | |
Some college | 5 (21) | 13 (21) | |
College graduate | 4 (17) | 14 (23) | |
Post graduate degree | 5 (21) | 7 (12) | |
Trade school | 1 (4) | 4 (7) | |
Incomec,d | |||
≤$10,000 | 0 (0) | 1 (2) | 0.76 |
$10,001–$25,000 | 4 (17) | 6 (10) | |
$25,001–$40,000 | 4 (17) | 15 (25) | |
$40,001–$55,000 | 4 (17) | 6 (10) | |
$55,001–$70,000 | 3 (13) | 8 (14) | |
$70,001–$85,000 | 3 (13) | 6 (10) | |
$85,001–$100,000 | 1 (4) | 9 (15) | |
>$100,000 | 4 (17) | 8 (14) | |
Diagnostic category | |||
ALL | 2 (8) | 2 (3) | <0.001 |
AML | 15 (60) | 17 (27) | |
CLL | 0 (0) | 9 (15) | |
CML | 5 (20) | 2 (3) | |
Lymphoma | 1 (4) | 22 (35) | |
MDS | 2 (8) | 8 (13) | |
Other | 0 (0) | 2 (3) | |
Donor type | |||
8/8 HLA matched unrelated donor | 14 (56) | 24 (39) | 0.14 |
HLA matched sibling donor | 11 (44) | 38 (61) | |
Graft typec | |||
Bone marrow | 5 (20) | 3 (5) | 0.03 |
Mobilized peripheral blood stem cells | 20 (80) | 56 (95) | |
CMV positivea | 9 (36) | 32 (53) | 0.17 |
Conditioning regimen | |||
Myeloablative | 12 (48) | 27 (44) | 0.71 |
Reduced intensity conditioning | 13 (52) | 35 (57) | |
Development of aGVHD (grades II–IV) | |||
Baseline | 0 (0) | 0 (0) | |
Day 28 | 0 (0) | 3 (5) | 0.26 |
Day 100 | 2 (8) | 10 (16) | 0.32 |
Day 180 | 3 (12) | 18 (29) | 0.09 |
